Based in San Diego, AnaBios is a translational CRO that specializes in ex vivo human tissue and primary cell models, offering highly predictive platforms across cardiac, pulmonary, neurological (hDRG), liver, kidney, and pain biology. Its human-centric services support drug de-risking and safety testing, and include the CardioPRIME® cardiac-slice platform. AnaBios holds FDA contracts and has expanded its offerings via the 2023 Cell Systems acquisition, enhancing access to primary endothelial cells for organ-chip and microfluidic research.